LeMaitre Vascular (NASDAQ:LMAT) Issues Q1 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its first quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.640-0.690 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $65.6 million-$67.6 million, compared to the consensus revenue estimate of $65.9 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.810-3.010 EPS.

LeMaitre Vascular Trading Down 6.7%

Shares of NASDAQ LMAT traded down $7.64 during midday trading on Friday, reaching $106.05. The company had a trading volume of 176,303 shares, compared to its average volume of 173,996. The stock has a market cap of $2.41 billion, a PE ratio of 42.18, a price-to-earnings-growth ratio of 2.03 and a beta of 0.72. LeMaitre Vascular has a one year low of $71.42 and a one year high of $115.33. The firm’s fifty day moving average price is $86.55 and its 200-day moving average price is $88.30. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 23.13%.The business had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same period last year, the company earned $0.49 EPS. LeMaitre Vascular’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. The ex-dividend date is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 31.87%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LMAT shares. Barrington Research raised their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday. Citizens Jmp raised their target price on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday. Wells Fargo & Company upped their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Finally, Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus price target of $106.50.

Key Headlines Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat expectations: LMAT reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M vs. $62.98M, with revenue up 15.7% year-over-year — a clear operational upside that supports earnings momentum. LeMaitre Q4 2025 Financial Results
• Positive Sentiment: Management raised guidance: Q1 EPS guided to $0.640–0.690 (vs. $0.620 consensus) and FY2026 EPS to $2.810–3.010 (vs. $2.61 consensus), plus higher revenue range — that forward raise is likely the primary bullish catalyst. LeMaitre (LMAT) Stock Trades Up, Here Is Why
• Positive Sentiment: Dividend increased 25% to $0.25 quarterly (annualized yield ~1.1%) — signals cashflow strength and returns capital to shareholders. Dividend Announcement
• Positive Sentiment: Analyst bullishness: Roth MKM reaffirmed “buy” and raised PT to $117; Citizens JMP raised PT to $118 with a market outperform — these upgrades can support further upside. Analyst Upgrades
• Neutral Sentiment: Earnings call and transcript provide color on growth drivers and execution (useful for investors but not an immediate price trigger). Q4 2025 Earnings Call Transcript
• Negative Sentiment: Mixed analyst picture and valuation friction: Wells Fargo raised its PT to $94 but kept an “equal weight” rating (below current levels), and Barrington’s $105 PT is roughly in line or slightly below recent prices — conflicting targets can prompt profit-taking. Mixed Analyst Targets
• Negative Sentiment: High valuation and recent run: LMAT trades with a high P/E (~42.5) and near its 52‑week high, so even positive news may trigger short-term selling as investors lock in gains. Valuation & Price Context

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund grew its holdings in shares of LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the period. NewEdge Advisors LLC grew its stake in shares of LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the period. Federated Hermes Inc. increased its position in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares during the last quarter. Equitable Holdings Inc. lifted its stake in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock worth $1,173,000 after purchasing an additional 205 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of LeMaitre Vascular by 1.7% in the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock worth $1,555,000 after buying an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.